Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-01-30
Просмотров: 477
Описание:
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents the updated results from a Phase Ib/II study (NCT03533283) investigating a combination of glofitamab and polatuzumab vedotin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received two or more prior lines of therapy. The safety profile of this combination therapy continues to be manageable due to a lack of overlapping toxicities of the two agents. The overall response rate (ORR) and complete response (CR) rate are promising, with responses demonstrating durability with longer follow-up. These encouraging results have been observed even in the sub-group of patients with high-grade B-cell lymphoma (HGBCL) and those with prior exposure to CAR T-cell therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Tumor microenvironment in a nutshell [WEBINAR]](https://imager.clipsaver.ru/UWMJMLpDh0E/max.jpg)
